See more : Emerald Resources NL (EMR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sun Pharmaceutical Industries Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hang Seng Bank Limited (HSNGF) Income Statement Analysis – Financial Results
- GLP J-REIT (3281.T) Income Statement Analysis – Financial Results
- Salon Media Group, Inc. (SLNM) Income Statement Analysis – Financial Results
- Coxon Precise Industrial Co., Ltd (3607.TW) Income Statement Analysis – Financial Results
- Standard Life Investments Property Income Trust Limited (SLI.L) Income Statement Analysis – Financial Results
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sunpharma.com
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 477.58B | 432.79B | 384.26B | 331.39B | 323.25B | 286.86B | 260.65B | 299.94B | 277.33B | 272.87B | 160.04B | 112.45B | 80.01B | 57.21B | 39.04B | 42.72B | 33.57B | 21.32B | 16.37B | 11.98B | 9.85B |
| Cost of Revenue | 248.12B | 106.62B | 117.08B | 98.85B | 104.71B | 92.39B | 88.26B | 94.25B | 74.91B | 77.76B | 33.78B | 25.34B | 19.82B | 14.61B | 10.98B | 8.56B | 7.22B | 5.77B | 4.87B | 3.23B | 2.39B |
| Gross Profit | 229.46B | 326.17B | 267.19B | 232.54B | 218.54B | 194.48B | 172.39B | 205.69B | 202.42B | 195.11B | 126.27B | 87.11B | 60.19B | 42.61B | 28.06B | 34.17B | 26.34B | 15.55B | 11.50B | 8.75B | 7.46B |
| Gross Profit Ratio | 48.05% | 75.36% | 69.53% | 70.17% | 67.61% | 67.79% | 66.14% | 68.58% | 72.99% | 71.50% | 78.90% | 77.46% | 75.23% | 74.47% | 71.88% | 79.97% | 78.48% | 72.95% | 70.24% | 73.02% | 75.77% |
| Research & Development | 31.28B | 23.08B | 21.33B | 21.03B | 19.25B | 19.13B | 20.52B | 21.46B | 22.24B | 18.37B | 9.86B | 6.62B | 0.00 | 2.86B | 2.08B | 3.10B | 2.73B | 2.44B | 1.53B | 0.00 | 0.00 |
| General & Administrative | 34.37B | 28.18B | 21.87B | 23.85B | 22.28B | 16.96B | 18.46B | 16.67B | 21.19B | 16.42B | 5.71B | 4.79B | 3.56B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 57.80B | 52.26B | 32.82B | 24.82B | 30.82B | 21.06B | 15.01B | 21.87B | 27.38B | 28.20B | 16.07B | 9.31B | 6.85B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 92.17B | 83.55B | 54.69B | 48.67B | 53.10B | 38.02B | 33.48B | 38.54B | 48.57B | 44.62B | 21.78B | 14.10B | 10.40B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 6.35B | 569.50M | 656.80M | 1.13B | 1.48B | 894.80M | 554.00M | 1.00B | 1.42B | 915.60M | 631.60M | 433.20M | 19.39B | 11.83B | 11.58B | 7.62B | 4.78B | 3.99B | 4.54B | 3.65B |
| Operating Expenses | 356.89B | 233.73B | 182.42B | 168.36B | 169.18B | 147.23B | 131.52B | 120.20B | 127.84B | 126.65B | 58.80B | 41.04B | 30.49B | 22.25B | 13.91B | 14.68B | 10.35B | 7.22B | 5.53B | 4.54B | 3.65B |
| Cost & Expenses | 379.17B | 340.35B | 299.49B | 267.21B | 273.90B | 239.62B | 219.78B | 214.45B | 202.74B | 204.41B | 92.57B | 66.38B | 50.31B | 36.86B | 24.89B | 23.23B | 17.57B | 12.99B | 10.40B | 7.77B | 6.03B |
| Interest Income | 10.23B | 3.59B | 5.53B | 2.11B | 3.55B | 6.69B | 5.20B | 3.71B | 2.66B | 2.57B | 2.06B | 2.37B | 1.98B | 2.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.38B | 1.72B | 1.27B | 1.41B | 2.91B | 5.25B | 4.52B | 3.30B | 2.41B | 1.81B | 223.80M | 368.90M | 282.00M | 738.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.57B | 25.29B | 21.44B | 20.80B | 20.53B | 17.53B | 15.00B | 12.65B | 10.14B | 11.95B | 4.09B | 3.36B | 2.91B | 2.04B | 1.53B | 1.23B | 968.60M | 813.30M | 610.20M | 406.00M | 285.70M |
| EBITDA | 138.36B | 120.85B | 67.00B | 49.99B | 73.13B | 60.84B | 54.04B | 106.73B | 80.78B | 81.77B | 74.56B | 46.95B | 36.76B | 22.98B | 15.68B | 20.72B | 16.96B | 9.15B | 6.58B | 4.62B | 4.10B |
| EBITDA Ratio | 28.97% | 28.38% | 30.19% | 27.32% | 23.25% | 25.08% | 23.63% | 35.36% | 31.13% | 29.51% | 47.07% | 46.88% | 46.01% | 39.15% | 40.17% | 48.51% | 50.54% | 42.91% | 40.20% | 38.51% | 41.62% |
| Operating Income | 104.68B | 93.05B | 81.47B | 64.28B | 49.48B | 47.37B | 40.87B | 85.49B | 74.58B | 68.46B | 67.47B | 46.06B | 29.71B | 20.36B | 14.15B | 19.49B | 15.99B | 8.33B | 5.97B | 4.21B | 3.81B |
| Operating Income Ratio | 21.92% | 21.50% | 21.20% | 19.40% | 15.31% | 16.51% | 15.68% | 28.50% | 26.89% | 25.09% | 42.16% | 40.96% | 37.13% | 35.58% | 36.24% | 45.62% | 47.65% | 39.09% | 36.47% | 35.13% | 38.72% |
| Total Other Income/Expenses | 6.20B | -124.96B | -36.44B | -36.99B | -98.25B | -9.08B | -5.91B | 5.63B | -9.26B | -4.21B | -21.63B | -2.84B | 3.86B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 110.88B | 94.08B | 44.81B | 27.99B | 50.10B | 38.10B | 34.79B | 90.48B | 67.65B | 64.03B | 45.83B | 43.21B | 33.56B | 20.36B | 14.15B | 19.49B | 15.99B | 8.33B | 5.97B | 4.21B | 3.81B |
| Income Before Tax Ratio | 23.22% | 21.74% | 11.66% | 8.45% | 15.50% | 13.28% | 13.35% | 30.17% | 24.39% | 23.47% | 28.64% | 38.43% | 41.95% | 35.58% | 36.24% | 45.62% | 47.65% | 39.09% | 36.47% | 35.13% | 38.72% |
| Income Tax Expense | 14.39B | 8.48B | 10.76B | 5.15B | 8.23B | 6.01B | 8.45B | 12.12B | 9.35B | 9.15B | 7.02B | 8.46B | 3.83B | 1.28B | 678.60M | 711.60M | 484.80M | -66.80M | 239.30M | 204.80M | 554.00M |
| Net Income | 95.76B | 84.74B | 32.73B | 29.04B | 37.65B | 26.65B | 21.62B | 69.64B | 47.16B | 45.39B | 31.41B | 29.83B | 25.87B | 18.16B | 13.47B | 18.78B | 15.51B | 8.40B | 5.73B | 4.00B | 3.31B |
| Net Income Ratio | 20.05% | 19.58% | 8.52% | 8.76% | 11.65% | 9.29% | 8.29% | 23.22% | 17.00% | 16.64% | 19.63% | 26.53% | 32.34% | 31.74% | 34.50% | 43.96% | 46.21% | 39.41% | 35.01% | 33.42% | 33.60% |
| EPS | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 | 11.11 | 9.01 | 29.00 | 18.90 | 18.90 | 15.20 | 14.40 | 12.85 | 8.75 | 6.50 | 8.78 | 7.47 | 4.17 | 3.09 | 2.14 | 3.54 |
| EPS Diluted | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 | 11.11 | 9.01 | 29.00 | 18.90 | 18.90 | 15.20 | 14.40 | 12.85 | 8.75 | 6.50 | 8.78 | 7.18 | 3.89 | 2.77 | 2.08 | 1.77 |
| Weighted Avg Shares Out | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.41B | 2.40B | 2.07B | 2.07B | 2.07B | 2.07B | 2.07B | 2.07B | 1.99B | 1.88B | 1.86B | 1.86B | 927.86M |
| Weighted Avg Shares Out (Dil) | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.40B | 2.41B | 2.41B | 2.07B | 2.07B | 2.07B | 2.07B | 2.07B | 2.07B | 2.07B | 2.02B | 2.07B | 1.91B | 1.86B |
Source: https://incomestatements.info
Category: Stock Reports